IC₅₀-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4

References

• Atkinson A, Kenny JR, Grime K. (2005). Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography–tandem mass spectrometry analysis. Drug Metab Dispos 33(11):1637–47.
   PubMed Web of Science ®Google Scholar
• Berry LM, Zhao Z. (2008). An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2(1):51–9.
   PubMedGoogle Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA; Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metabolism/Clinical Pharmacology Technical Working Group; FDA Center for Drug Evaluation and Research (CDER). (2003). The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815–32.
   PubMed Web of Science ®Google Scholar
• Brown HS, Ito K, Galetin A, Houston JB. (2005). Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 60(5):508–18.
   PubMed Web of Science ®Google Scholar
• Egnell AC, Houston B, Boyer S. (2003). In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine. J Pharmacol Exp Ther 305(3):1251–62.
   PubMed Web of Science ®Google Scholar
• Ernest CS 2nd, Hall SD, Jones DR. (2005). Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312(2):583–91.
   PubMed Web of Science ®Google Scholar
• Fowler S, Zhang H. (2008). In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug–drug interactions. AAPS J 10(2):410–24.
   PubMed Web of Science ®Google Scholar
• Galetin A, Burt H, Gibbons L, Houston JB. (2006). Prediction of time-dependent CYP3A4 drug–drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34(1):166–75.
   PubMed Web of Science ®Google Scholar
• Galetin A, Gertz M, Houston JB. (2008). Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions. Expert Opin Drug Metab Toxicol 4(7):909–22.
   PubMed Web of Science ®Google Scholar
• Galetin A, Hinton LK, Burt H, Obach RS, Houston JB. (2007). Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug–drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 8(7):685–93.
   PubMed Web of Science ®Google Scholar
• Galetin A, Ito K, Hallifax D, Houston JB. (2005). CYP3A4 substrate selection and substitution in the prediction of potential drug–drug interactions. J Pharmacol Exp Ther 314(1):180–90.
   PubMed Web of Science ®Google Scholar
• Gertz M, Davis JD, Harrison A, Houston JB, Galetin A. (2008). Grapefruit juice–drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations. Curr Drug Metab 9(8):785–95.
   PubMed Web of Science ®Google Scholar
• Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, Rostami-Hodjegan A. (2006). A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7(3):315–34.
   PubMed Web of Science ®Google Scholar
• Grime KH, Bird J, Ferguson D, Riley RJ. (2009). Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods. Eur J Pharm Sci 36(2–3):175–91.
   PubMed Web of Science ®Google Scholar
• Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Van Horn R, Wang RW, Wong YN, Yang TJ, Obach RS. (2009). The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37(7):1355–70.
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. (2006). Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34(4):724–6; author reply 727.
   PubMed Web of Science ®Google Scholar
• Houston JB, Galetin A. (2008). Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9(9):940–951.
   PubMed Web of Science ®Google Scholar
• Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, Chung S, Colangelo P, Frucht D, Green MD, Hepp P, Karnaukhova E, Ko HS, Lee JI, Marroum PJ, Norden JM, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei XX, Yasuda S, Zheng JH, Zhao H, Lesko LJ. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48(6):662–70.
   PubMed Web of Science ®Google Scholar
• Huang SM, Temple R, Throckmorton DC, Lesko LJ. (2007). Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81(2):298–304.
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. Br J Clin Pharmacol 57(4):473–86.
   PubMed Web of Science ®Google Scholar
• Ito K, Ogihara K, Kanamitsu S, Itoh T. (2003). Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31(7):945–54.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Obach RS, Maurer TS. (2007). Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 8(5):407–47.
   PubMed Web of Science ®Google Scholar
• Krippendorff BF, Neuhaus R, Lienau P, Reichel A, Huisinga W. (2009). Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values. J Biomol Screen 14(8):913–23.
   PubMedGoogle Scholar
• Maurer TS, Tabrizi-Fard MA, Fung HL. (2000). Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery. J Pharm Sci 89(11):1404–14.
   PubMed Web of Science ®Google Scholar
• Obach RS. (1997). Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25(12):1359–69.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 35(2):246–55.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. (2006). The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J Pharmacol Exp Ther 316(1):336–48.
   PubMed Web of Science ®Google Scholar
• Ogilvie BW, Yerino P, Paris B, Parkinson A. (2007). Effects of substrate incubation time on the IC50 shift for mechanism-based inhibition of CYP1A2 and 3A4. Drug Metab Rev 39:222.
   Web of Science ®Google Scholar
• Paris B, Kazmi F, Buckley D, Ogilvie B, Gipson A, Parkinson A. (2009). Pitfalls in the design of CYP inhibition studies incorporating a dilution step to examine time-dependent inhibition (TDI) or metabolism-dependent inhibition (MDI). Drug Metab Rev 41(Suppl 3):92.
   Google Scholar
• Perloff ES, Mason AK, Dehal SS, Blanchard AP, Morgan L, Ho T, Dandeneau A, Crocker RM, Chandler CM, Boily N, Crespi CL, Stresser DM. (2009). Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC50 shift approach facilitates kinact assay design. Xenobiotica 39(2):99–112.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Miners JO. (2007). In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3(3):321–329.
   PubMed Web of Science ®Google Scholar
• Riley RJ, Grime K, Weaver R. (2007). Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3(1):51–66.
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker G. (2004). ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactions. Drug Discovery Today: Technol 1(4):441–8.
   PubMedGoogle Scholar
• Sheiner LB, Beal SL. (1981). Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4):503–12.
   PubMedGoogle Scholar
• Silverman RB. (1995). Mechanism-based enzyme inactivators. Meth Enzymol 249:240–83.
   PubMed Web of Science ®Google Scholar
• Stringer RA, Strain-Damerell C, Nicklin P, Houston JB. (2009). Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions. Drug Metab Dispos 37(5):1025–34.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment. Xenobiotica 37(10-11):1225–56.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Durol AL, Duan SX, Greenblatt DJ. (2000). Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 56(3):259–61.
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. (2004). Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32(2):259–66.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Suzuki A, Kohno Y. (2004). High-throughput screening for the assessment of time-dependent inhibitions of new drug candidates on recombinant CYP2D6 and CYP3A4 using a single concentration method. Xenobiotica 34(1):87–101.
   PubMed Web of Science ®Google Scholar
• Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. (2008). Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9(5):384–94.
   PubMed Web of Science ®Google Scholar
• Yeo KR, Yeo WW. (2001). Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 51(5):461–470.
   PubMed Web of Science ®Google Scholar